Quarterly report [Sections 13 or 15(d)]

Other current assets

v3.25.1
Other current assets
3 Months Ended
Mar. 31, 2025
Other current assets  
Other current assets

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):

March 31, 

December 31, 

    

2025

2024

Research and development credits receivable

 

$

14,693

$

12,929

Prepayments

 

7,475

10,033

Clinical materials

 

59

VAT receivable

1,777

1,599

Other current assets

 

3,349

3,170

$

27,294

$

27,790

Research and development credits receivable as of March 31, 2025 primarily relate to the claim for the year ended December 31, 2024.